Tyra Biosciences (NASDAQ:TYRA) Sets New 52-Week High – What’s Next?

Tyra Biosciences, Inc. (NASDAQ:TYRA)’s stock price reached a new 52-week high on Thursday . The stock traded as high as $34.50 and last traded at $30.5570, with a volume of 30897 shares. The stock had previously closed at $30.00.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tyra Biosciences in a research report on Wednesday, January 21st. Wedbush upped their target price on shares of Tyra Biosciences from $30.00 to $37.00 and gave the company an “outperform” rating in a report on Tuesday, December 16th. Barclays started coverage on Tyra Biosciences in a report on Tuesday, January 27th. They set an “overweight” rating for the company. Jefferies Financial Group boosted their price target on Tyra Biosciences from $32.00 to $43.00 and gave the stock a “buy” rating in a research report on Tuesday, February 3rd. Finally, William Blair began coverage on Tyra Biosciences in a research report on Tuesday. They issued an “outperform” rating for the company. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $37.17.

Tyra Biosciences Stock Performance

The company has a fifty day moving average of $27.38 and a two-hundred day moving average of $18.67. The firm has a market capitalization of $1.57 billion, a price-to-earnings ratio of -15.69 and a beta of 1.07.

Insider Activity at Tyra Biosciences

In related news, Director Robert J. More sold 246,871 shares of the firm’s stock in a transaction dated Friday, November 21st. The shares were sold at an average price of $20.25, for a total transaction of $4,999,137.75. Following the transaction, the director directly owned 3,833,425 shares of the company’s stock, valued at approximately $77,626,856.25. This trade represents a 6.05% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 15.20% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Federated Hermes Inc. raised its position in shares of Tyra Biosciences by 586.3% in the third quarter. Federated Hermes Inc. now owns 2,155 shares of the company’s stock valued at $30,000 after buying an additional 1,841 shares in the last quarter. Chung Wu Investment Group LLC acquired a new position in Tyra Biosciences in the 4th quarter valued at $53,000. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Tyra Biosciences by 25.9% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,594 shares of the company’s stock valued at $68,000 after acquiring an additional 534 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Tyra Biosciences by 14.5% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 13,182 shares of the company’s stock worth $126,000 after purchasing an additional 1,668 shares in the last quarter. Finally, SG Americas Securities LLC bought a new position in shares of Tyra Biosciences in the third quarter worth $133,000. Institutional investors and hedge funds own 84.14% of the company’s stock.

Tyra Biosciences Company Profile

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.